Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cvac Maintenance in Ovarian Cancer
NCT01068509Phase 2Completed
- Sponsor
- Immutep Limited
- Start
- Jul 2010
- Primary completion
- Aug 2013
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of CVac in epithelial ovarian cancer (EOC) (3 arms), sponsored by Immutep Limited. Primary endpoint: Progression-free Survival at 48 weeks. Started Jul 2010; status: completed.
02
Drugs
CVac
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT01068509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068509.